However, the findings support that inhibition of PPARβ/δ-associated pathways may interfere with central leptin’s beneficial effects in the heart, which may be relevant in patients with conditions like generalized lipodystrophy where leptin therapy is used to mitigate cardiac hypertrophy [45]. Here, PPARD is linked to cardiac hypertrophy.